Treatment and follow-up
toxicity, death, Tumor, TRAEs
ADVERSE EVENTS, DISEASE PROGRESSION, TUMOR
Patients were administered oral icotinib (125 mg three times per day) and anlotinib (12 mg once per day). Each cycle of anlotinib treatment was defined as 2 weeks on-treatment followed by 1 week off-treatment. Treatment was continued until disease progression, intolerable toxicity, or patient request of discontinuation. Dose adjustments were judged by the investigators based on treatment-related adverse events (TRAEs) following the NCI-CTCAE v4.0 criteria. Dose modifications (10 mg/d or 8 mg/d) of anlotinib were allowed according to the protocol-defined dose modification criteria. In case of dose reduction, the patient was not allowed to return to the previous dose level; if the dose of 8 mg/d was not tolerated, the treatment was permanently terminated.Tumor response was evaluated every 6 weeks based on RECIST 1.1. Patient follow-up was performed to assess clinical outcomes, including toxicity, efficacy, and survival, until death. Follow-up for survival was performed via clinical visits or telephone calls every 12 weeks.